Joseph Ross

Now we're in March and we're starting to see some treatment trials.

We're starting to see more prognosis papers.

You know, the earliest papers were Chinese populations.

Now we're seeing lots of papers from Europe and the United States.

You know, it's reflecting, you know, where the disease is.

The goal is not to, you know, inform patients.

It's not to inform the frontline clinicians, but it's to enable scientists to communicate and learn from each other more easily, to build on each other's work and to sort of know

what other people are doing to refine their own approaches.

So that is our key sort of stakeholder.

And that's what we always want to know is, is it serving the needs of the scientific community?

And what can we do to strengthen it to do that better?

What I would say is, I mean, there's two kind of interesting takeaways from this.

First is, it's amazing that scientists and physicians in the middle of an epidemic are taking the time to write up

you know, what they're experiencing.

And it's not always like a perfectly final paper that you would have seen in the BMJ or JAMA or something like that.

But people are taking their time to do the best job to write up what they're seeing and analyze their data as accurately as possible.

And so that, you know, to give to the community.

But it's just enabled much faster communication.

People are able to learn from each other.

And this is really critical as communities are faced with this pandemic so that